Po22-693 Inhibition of Plasma Oxidation and Reduction of Leukotriene B4 Release After Oral Administration of Agi-1067, a Novel Anti-Atherosclerotic Agent

Kunsch, Charles; Qiu, F-H.; Suen, K-L.; Shao, Nan; Simmons, Laura; Weingarten, M. David; Smith, J. B.; Cook, Carrie; Small, Ralph E.; Xc, Xu; Scott, R. A. D.

doi:10.1016/s1567-5688(07)71703-8

Atherosclerosis Supplements

2007

DOI: 10.1016/s1567-5688(07)71703-8

|View full text |Cite

Po22-693 Inhibition of Plasma Oxidation and Reduction of Leukotriene B4 Release After Oral Administration of Agi-1067, a Novel Anti-Atherosclerotic Agent

Charles Kunsch¹,

F-H. Qiu²,

K-L. Suen³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects

Muldrew

Franks

2009

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Background: Succinobucol (AGI-1067) was developed as a probucol derivative with anti-inflammatory and antioxidant properties. It has undergone Phase III clinical trials to determine its place in the treatment of atherosclerotic disease. Objective: This paper reviews the available history, pharmacology and preclinical and clinical trial data of succinobucol. Methods: Data were compiled following review of publications indexed in Medline and International Pharmaceutical Abstracts, industry media releases and relevant bibliographies. Results/conclusion: In preclinical studies, succinobucol exhibited antioxidant, anti-inflammatory, antihyperglycemic and antiplatelet properties; however, these effects have not resulted in a reduction in cardiovascular clinical end points in clinical trials. Although proposed antihyperglycemic effects are being investigated, safety concerns and lack of clear cardiovascular benefit may limit its clinical use as an antihyperglycemic agent.

show abstract

Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects

Muldrew

Franks

2009

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Po22-693 Inhibition of Plasma Oxidation and Reduction of Leukotriene B4 Release After Oral Administration of Agi-1067, a Novel Anti-Atherosclerotic Agent

Cited by 1 publication

References 0 publications

Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects

Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects

Contact Info

Product

Resources

About